EcPLA

  1. Home
  2. Wiki

EcPLA
Clinical data
Other namesECYPLA; N-Ethyl-N-cyclopropyllysergamide
Routes of
administration		Oral
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
Identifiers
  • (6aR,9R)-N-cyclopropyl-N-ethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC21H25N3O
Molar mass335.451 g·mol−1
3D model (JSmol)
  • CCN(C1CC1)C(=O)[C@@H]3C=C2c4cccc5ncc(C[C@H]2N(C)C3)c45
  • InChI=1S/C21H25N3O/c1-3-24(15-7-8-15)21(25)14-9-17-16-5-4-6-18-20(16)13(11-22-18)10-19(17)23(2)12-14/h4-6,9,11,14-15,19,22H,3,7-8,10,12H2,1-2H3/t14-,19-/m1/s1
  • Key:UNUJKEQFYPYXBK-AUUYWEPGSA-N

EcPLA, also known as N-ethyl-N-cyclopropyllysergamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[2][3] It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA.[3][2][4]

Interactions

[edit]
See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets.[3] It is a potency agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[3]

The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[3] It has about 40% of the potency of LSD in this regard.[3]

Pharmacokinetics

[edit]

The in-vitro metabolism of EcPLA has been studied.[5]

Chemistry

[edit]

Analogues

[edit]

Analogues of EcPLA include MiPLA, LAMPA (MPLA), EPLA, EiPLA, ETFELA, and LSZ, among others.[4][3][2]

History

[edit]

EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019.[3] It was developed by Lizard Labs.[citation needed]

See also

[edit]

References

[edit]
  1. ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". www.legifrance.gouv.fr (in French). 20 May 2021.
  2. ^ a b c Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Halberstadt AL, et al. (2020). "Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. 12 (10): 1514–1521. doi:10.1002/dta.2911. ISSN 1942-7611. PMC 9191644. PMID 32803833.
  3. ^ a b c d e f g h Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. (February 2019). "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)". Psychopharmacology. 236 (2): 799–808. doi:10.1007/s00213-018-5055-9. PMC 6848745. PMID 30298278.
  4. ^ a b Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P (January 2025). "A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies". Analyst. 150 (2): 290–308. doi:10.1039/d4an01361a. PMID 39636448.
  5. ^ Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, et al. (July 2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures" (PDF). Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9. PMID 30617391. S2CID 58615418.
[edit]